BioDrive, Inc.
Has BioDrive, Inc. received an FDA warning letter? Yes. FDA issued a warning letter dated August 24, 2026.
Letter facts
- Letter date
- August 24, 2026 (2026-08-24)
- Issuing office
- Human Foods Program
- Products named
- Evolv GLP-1 Biomimetic dietary supplement
- Violation categories
- Other
Understanding these violation categories
Other
FDA cited violations of federal regulations governing drug research, clinical trials, or product distribution. A warning letter is an advisory notice allowing the recipient to respond.
Factual Violation Summary
FDA says Evolv GLP-1 Biomimetic contains EV1-Peptide, a new dietary ingredient with inadequate safety information and potential toxicity concerns; FDA deemed it adulterated under section 402(f)(1)(B) despite two NDIN objections.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Adulterated dietary supplement
- New dietary ingredient (NDI) without adequate safety information
- Introduction of adulterated product into interstate commerce
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Other)
Recent warning letters with related regulatory findings:
- Novo Nordisk Inc.March 5, 2026
- Ralph A. DeFronzo, M.D.September 17, 2025
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.